Metabolite ratios, white/grey matter ratios, and CSF to intracranial volume ratios for the five patients. Means (SD) from the seronegative high risk control group are also given. Time = Time relative to the commencement of antiretroviral therapy
Time (weeks) | NA/(NA+Cho+Cr) | NA/Cr | NA/Cho | Cho/Cr | Cwg | CSF/ICV | HADC status2-150 | |
---|---|---|---|---|---|---|---|---|
Patient 1 | −7.6 | 0.42 | 1.72 | 1.26 | 1.36 | 1.02 | 0.15 | – |
8.7 | 0.54 | 2.29 | 2.39 | 0.96 | 1.02 | 0.17 | Improvement | |
20.1 | 0.40 | 1.48 | 1.23 | 1.20 | 0.93 | 0.18 | Deterioration | |
Patient 2 | 0.0 | 0.31 | 1.00 | 0.81 | 1.23 | 1.11 | 0.18 | – |
3.8 | 0.47 | 1.96 | 1.68 | 1.17 | 1.08 | 0.22 | Improvement | |
15.2 | 0.41 | 1.72 | 1.19 | 1.44 | 1.13 | 0.23 | Deterioration | |
Patient 3 | −2.0 | 0.45 | 1.78 | 1.52 | 1.17 | 1.00 | 0.18 | – |
−0.8 | 0.46 | 1.64 | 1.71 | 0.96 | 1.03 | 0.19 | – | |
13.2 | 0.52 | 2.16 | 2.16 | 1.00 | 0.89 | 0.24 | Improvement | |
Patient 4 | −0.3 | 0.55 | 2.30 | 2.56 | 0.90 | 1.34 | 0.12 | – |
6.7 | 0.51 | 2.42 | 1.77 | 1.37 | 1.45 | 0.13 | Improvement | |
Patient 5 | −0.1 | 0.44 | 1.59 | 1.52 | 1.05 | 0.93 | 0.22 | – |
4.7 | 0.51 | 2.20 | 1.94 | 1.13 | 0.94 | 0.26 | No change2-151 | |
Controls (n=17) (mean (SD)) | — | 0.54 (0.04) | 2.31 (0.49) | 2.58 (0.68) | 0.94 (0.27) | 0.93 (0.05) | 0.13 (0.03) | – |